A follow-up phase II randomized trial compared the FOLFIRI regimen to a high-dose irinotecan FOLFIRI regimen in colorectal cancer patients, where UGT1A1 NMsin the high-dose FOLFIRI cohort received 300 mg/m2 irinotecan [66]. This evidence concerns the gene UGT1A1 and colorectal cancer.